Evidence base to support using prescribed psychostimulants to treat psychostimulant use disorder is limited.
Anees Bahji, Marlon Danilewitz, Tony P George, Arash Dhaliwal, David N Crockford
Author Information
- Anees Bahji: Clinical assistant professor, Department of Psychiatry, University of Calgary, Calgary, Alta.
- Marlon Danilewitz: Associate conference chair, Canadian Psychiatric Association, Ottawa, Ont.; assistant professor, Department of Psychiatry, University of Toronto, Toronto, Ont.; associate medical director, General Psychiatry, Ontario Shores Centre for Mental Health Sciences, Whitby, Ont.
- Tony P George: Professor, Department of Psychiatry, University of Toronto, Toronto, Ont.
- Arash Dhaliwal: Assistant professor, Department of Psychiatry, Western University, London, Ont.
- David N Crockford: Clinical professor, Department of Psychiatry, University of Calgary, Calgary, Alta.
No abstract text available.
- CMAJ. 2023 Jul 17;195(27):E934-E935
[PMID: 37460124]
- BMC Public Health. 2022 Nov 15;22(1):2084
[PMID: 36380298]
- Psychopharmacology (Berl). 2020 Aug;237(8):2233-2255
[PMID: 32601988]
- CNS Drugs. 2020 Apr;34(4):337-365
[PMID: 32185696]
- PLoS One. 2020 Jun 18;15(6):e0234809
[PMID: 32555667]
- R25 DA037756/NIDA NIH HHS
Humans
Central Nervous System Stimulants
Attention Deficit Disorder with Hyperactivity
Central Nervous System Stimulants
